SNDX · Company research
Syndax Pharmaceuticals, Inc. (SNDX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
20records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals (SNDX) Stock May Be Fully Priced After Trial Setback - Simply Wall Street | Syndax Pharmaceuticals (SNDX) Stock May Be Fully Priced After Trial Setback Simply Wall Street | View source ↗ | Simply Wall Street | Oct 16, 2026 | neutral | 0 | 0.6 |
| TIME's 2026 inventions list includes a drug for some leukemia patients as young as 1 - Stock Titan | TIME's 2026 inventions list includes a drug for some leukemia patients as young as 1 Stock Titan | View source ↗ | Stock Titan | Oct 15, 2026 | neutral | 0 | 0.6 |
| Syndax Pharmaceuticals (SNDX) Stock Dropped, So What Is Behind The Move? - Simply Wall Street | Syndax Pharmaceuticals (SNDX) Stock Dropped, So What Is Behind The Move? Simply Wall Street | View source ↗ | Simply Wall Street | Oct 14, 2026 | neutral | 0 | 0.6 |
| Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal | Syndax Pharmaceuticals (SNDX) shares fell 15.7% after its phase II MAXPIRe study of axatilimab failed to meet the primary endpoint in idiopathic pulmonary fibrosis (IPF) treatment. The drug showed no benefit in slowing FVC decline, though it maintained a favorable safety profile. The company is discontinuing IPF development but will continue pursuing axatilimab in chronic graft-versus-host disease (cGVHD) with results expected in 2026 and 2028. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | neutral | 0 | 1 |
| Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal - TradingView | Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal TradingView | View source ↗ | TradingView | Oct 14, 2026 | neutral | 0 | 0.6 |
| Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX) - PR Newswire | Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX) PR Newswire | View source ↗ | PR Newswire | Oct 14, 2026 | neutral | 0 | 0.6 |
| Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down - Here's What Happened - MarketBeat | Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down - Here's What Happened MarketBeat | View source ↗ | MarketBeat | Oct 13, 2026 | neutral | 0 | 0.6 |
| $SNDX stock is down 18% today. Here's what we see in our data. - Quiver Quantitative | $SNDX stock is down 18% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 13, 2026 | neutral | 0 | 0.6 |
| Syndax Pharmaceuticals (SNDX) Is Down 7.2% After Axatilimab IPF Trial Misses Endpoint Has The Bull Case Changed? - Yahoo Finance | Syndax Pharmaceuticals (SNDX) Is Down 7.2% After Axatilimab IPF Trial Misses Endpoint Has The Bull Case Changed? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 13, 2026 | neutral | 0 | 0.6 |
| SNDX Stock Slumps 16% After-Hours — What’s Driving The Selloff? - Yahoo Finance | SNDX Stock Slumps 16% After-Hours — What’s Driving The Selloff? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 12, 2026 | neutral | 0 | 0.6 |
| Syndax Pharmaceuticals (SNDX) Shares Drop 15% After Phase 2 Tria - GuruFocus | Syndax Pharmaceuticals (SNDX) Shares Drop 15% After Phase 2 Tria GuruFocus | View source ↗ | GuruFocus | Oct 12, 2026 | neutral | 0 | 0.6 |
| SNDX Stock Slumps 16% After-Hours — What’s Driving The Selloff? - Stocktwits | SNDX Stock Slumps 16% After-Hours — What’s Driving The Selloff? Stocktwits | View source ↗ | Stocktwits | Oct 12, 2026 | neutral | 0 | 0.6 |
| Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock Now Rated "Moderate Buy" by Sell-Side Analysts - MarketBeat | Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock Now Rated "Moderate Buy" by Sell-Side Analysts MarketBeat | View source ↗ | MarketBeat | Oct 9, 2026 | neutral | 0 | 0.6 |
| Nine new hires received rights to buy up to 213,300 Syndax shares, vesting over four years. - Stock Titan | Nine new hires received rights to buy up to 213,300 Syndax shares, vesting over four years. Stock Titan | View source ↗ | Stock Titan | Oct 2, 2026 | neutral | 0 | 0.6 |
| Syndax Pharmaceuticals (SNDX) Stock Looks Fully Valued After Its 21% Gain - Webull | Syndax Pharmaceuticals (SNDX) Stock Looks Fully Valued After Its 21% Gain Webull | View source ↗ | Webull | Sep 25, 2026 | neutral | 0 | 0.6 |
| Syndax Pharmaceuticals: Buy The Pullback Ahead Of Q4 Readouts (NASDAQ:SNDX) - Seeking Alpha | Syndax Pharmaceuticals: Buy The Pullback Ahead Of Q4 Readouts (NASDAQ:SNDX) Seeking Alpha | View source ↗ | Seeking Alpha | Sep 25, 2026 | neutral | 0 | 0.6 |
| Syndax Pharmaceuticals (SNDX) Stock Looks Fully Valued After Its 21% Gain - Simply Wall Street | Syndax Pharmaceuticals (SNDX) Stock Looks Fully Valued After Its 21% Gain Simply Wall Street | View source ↗ | Simply Wall Street | Sep 23, 2026 | neutral | 0 | 0.6 |
| Syndax Pharmaceuticals (SNDX) Stock May Be Pricey Following A 15% Gain - Webull | Syndax Pharmaceuticals (SNDX) Stock May Be Pricey Following A 15% Gain Webull | View source ↗ | Webull | Sep 12, 2026 | neutral | 0 | 0.6 |
| Syndax (SNDX) Sales Nearly Doubled, So Why Did The Stock Fall? - Yahoo Finance | Syndax (SNDX) Sales Nearly Doubled, So Why Did The Stock Fall? Yahoo Finance | View source ↗ | Yahoo Finance | Aug 12, 2026 | neutral | 0 | 0.6 |
| SNDX Forecast — Price Target — Prediction for 2027 - TradingView | SNDX Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.